• The Therapeutic Area Lead is responsible for a broad range of medical affairs and cross-functional activities, particularly for launch preparations and setting the stage and building the foundations of a successful go-to-market strategy and life cycle management, such as early engagement and information, mapping, gathering of insights, provision of scientific expertise, communication of the medical value brought to patients, building of sustainable relationships, founding collaborations and support data generation

Indications and agents:

• I131-Apamistamab (Iomab B) in relapse or refractory Acute Myeloid Leukemia (AML), Akynzeo in CINV, Pegzilarginase in hyperargininaemia, a rare disease, and other compounds in the treatment of rare urea cycle disorders (UCDs)

• As a member of the DACH region leadership circle, the MD leads and manages the medical affairs team (16 people) and a broad range of medical affairs and cross functional activities, such as the preparation and follow-up of investigator initiated study (IIS) programs, support of national and international clinical studies (including site selection, patient recruitment), real world evidence (RWE) generation, intensive external expert management, review of medical affairs materials/promotional materials, official medical communication, national advisory boards and investigator meetings, educational and training activities, publications, and medical educational grants.

Indications and agents:

• Breast Cancer (BC, Neratinib), Melanoma (Encorafenib/Binimetinib), Colorectal Cancer (CRC) and Non-Small-Cell Lung Cancer (NSCLC) [Encorafenib], and Tablecleucel in Epstein-Barr virus positive post-transplant lymphoproliferative disease (PTLD, a rare disease)

• This is a highly cross-functional leadership role in medical affairs in Europe, managing four reports and located amidst strategy and operationalization. The function is responsible for building, planning and local rolling out the KOL strategy, its execution and reporting of KPIs. KOL engagement leadership, collaboration, alignment of objectives and tactics are key deliverables for this role. Other responsibilities include annual strategic kick-off meetings and regular townhalls, the European Medical Information System, development activities and trainings for MSLs and other medical affairs functions in the countries as well as strong support for brand teams, harmonization of launch activities and patient advocacy.

Highlights:

• Launch of Enhertu (T-DXd), building and launching of a pan-European KOL planning and management system, implementation of the Medical Affairs Academy (MEA), and a pan-European guidance white paper on roles and responsibilities of MSLs

Indications and agents:

• T-DXd in Breast-, Lung and Gastric Cancer, a broad range of pipeline products in solid tumors, hematology and TGCT (rare), Edoxaban in cardiology, Nilemdo/Nustendi in lipidiology

• This is a leadership role in medical affairs in Germany managing 11 reports. The MD actively participates/leads the preparation and provides oversight of investigator sponsored trial (IST) programs, national and international clinical studies (including site selection, patient recruitment), external expert management, review of materials, official medical communication, national advisory boards and investigator meetings, educational and training activities, publications, and medical educational grants 

Indications and agents:

• covering a broad range of pipeline products in solid tumors and hematology, and Chronic Myeloid Leukemia (CML), Ph+ Acute Myeloid Leukemia (ALL) with Iclusig (Ponatinib)

• HQ based Medical Affairs, highly exposed role in an international matrix environment, key point of medical contact for project management, clinical development, regulatory, market access and commercial as well as all country stakeholders; development and worldwide implementation and execution of the global Medical Affairs strategy and publication plan, representation of the company to scientific societies and the external medical community; conducting advisory boards, symposia and trainings; conception, design and managing of studies, complex data sets, results and reports

Indications and agents:

• Neutropenia, in particular across Oncology/Hematology indications (Breast Cancer, NHL, Lung Cancer, others), Anemia - Filgrastim, Pegfilgrastim and Erythropoietin

• HQ based, highly cross-functional role in an international matrix environment, key point of contact for countries and stakeholders, responsible for G-CSF portfolio worldwide, inline and pipeline; development, implementation and execution of the global strategy- and brand plan

Indications and agents:

• Neutropenia across Oncology/Hematology indications (Breast Cancer, NHL) - Filgrastim, Pegfilgrastim

Special:

• Launch of Zarxio, 1st biosimilar approved by the FDA; usage of Filgrastim for the treatment of Amyotrophic Lateral Sclerosis (ALS)

• Responsible for launch-preparations and inline products in 16 EU-countries, Africa and Middle East; development, implementation and execution of the global brand plan on a regional level, trainings, KOL management, regional advisory boards and educational events

Indications and agents:

• CML ? Bosulif (Bosutinib), MCL - Torisel (Temsirolimus), NHL/ALL ? Inotuzumab

Special:

• European Launch of Bosulif

• Development, implementation and execution of the global brand plan on a local level administration of product-, project-, and congress management for Nexavar (Sorafenib) in RCC and HCC, trainings, KOL-management, local advisory boards, symposia and other educational events

Other indications and agents:

• NSCLC, Thyriod-Ca, Colon-Ca, CLL ? MabCampath (Alemtuzumab), Follicular Lymphoma ? Zevalin (90Yttrium-Ibritumomab-Tiuxetan)

Special:

• Continued medical affairs projects -symposia, educational events, medical writing, conduct of a single center study regarding prognostic factors of HCC patients undergoing Nexavar therapy, management of scientific grants and a ministry funded study regarding the use of phosphoproteomics in AML treated with Nexavar

• Scientific-medical communication regarding the use of Nexavar and further oncology portfolio in various tumor entities, externally, and in supporting of marketing and sales functions, medical trainings, medical writing, managing of studies, local advisory boards, symposia and other educational events

Special:

• Launch of Nexavar in HCC

• High level sales representative, a one-face-to-the-customer role, account management, KOL-management, hospital and private practice sales

Special:

• Launch of Nexavar in RCC

• Focus on growth factors - Neupogen (Filgrastim), Neulasta (Pegfilgrastim) in NonHodgkin Lymphoma, Mamma-Ca and Stemcell-Transplantation; Aranesp (Darbepoetin Alfa) in hematotoxic regimen and Kepivance (Palifermin) for oral mucositis during myeloablative therapy

Special:

• Launch of Aranesp as long-term application, pen-applicator for Aranesp and Neulasta, launch of Kepivance